Please ensure Javascript is enabled for purposes of website accessibility

What Bipartisan Health-Care Reform Means for Investors

By Brian Orelli, PhD – Updated Apr 6, 2017 at 1:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Republicans and Democrats will debate on TV, but little may come of it.

Mark your calendars, investors; Feb. 25 could change the scope of health care in the U.S. Alternately, it could just be a waste of half of a day in front of the TV.

Since Democrats lost their filibuster-proof majority, making it harder to get health-care reform through the Senate, President Obama has decided to try an alternative route: a bipartisan compromise.

Unfortunately, inviting Republicans to the bargaining table, at a meeting which will be televised later this month, may end up being more political theater than actual lawmaking. As much as investors would like to see closure, Feb. 25 may not get us any closer to wrapping up the issue that's been weighing on health-care stocks for months.

Too far apart?
Republicans want to start anew by shelving the unmerged bills that were passed by the House and Senate. Democrats seem to be looking for just enough tweaking of the current bills to get enough Republicans on board to get it through the Senate.

Alternatively, Democrats would probably be just as happy portraying Republicans as obstructionists, with the hope that voters will replace enough Republicans with Democrats in November so that health-care reform can pass next year.

That pressure could result in some toned-down version being passed, which would make both sides look like winners, but might hurt investors -- and consumers -- more than the current bloated bills.

Half a fix may be worse than no fix at all
There are two major problems with the U.S. health care system today: It's very expensive, and there are many people who don't have insurance. The two are ultimately tied together, both financially -- I would imagine many of the 26.9% of Texans who don't have insurance would buy it if it was cheap enough -- and politically.

The solution is to get everyone into the risk pool, where the uninsured well people can help pay for the uninsured sick people. With universal health care off the table, that leaves politicians requiring everyone to get insurance through private insurers such as UnitedHealth Group (NYSE:UNH), WellPoint (NYSE:WLP), and Aetna (NYSE:AET). Without mandated health insurance, insurers can't afford to insure people with preexisting conditions.

But the government would have to subsidize insurance for many poor people, which means extracting concessions from other areas of health care: drugmakers like Pfizer (NYSE:PFE) and Merck (NYSE:MRK), medical-device makers like Boston Scientific (NYSE:BSX) and Medtronic (NYSE:MDT), and even doctors who cover Medicare patients. Unless we'd like to bloat the deficit even more, we need those concessions.

With the entire system intertwined, I'm not sure it will solve anything or help anyone to pass a watered-down version of health-care reform. The worst-case scenario for investors is that politicians try to punish health-care companies with higher taxes, but don't give them extra patients through mandated health insurance.

More uncertainty ahead
Uncertainty can be profitable -- if you're on the correct side of the decision -- and there are health-care plays that should work well whether reform passes or not. But I'd just as soon get the debate over with and see health-care stocks return to trading on fundamentals. You know -- things like revenue, profits, and cash flows, rather than what politicians are currently saying.

Unfortunately, this debate seems far from over. While I hope something productive will come from the bipartisan meeting later this month, I'm not expecting much more than politics as usual.

What do you think will happen to health-care reform? Is a bipartisian compromise the best answer? Let us know in the comments box below.

Pfizer, UnitedHealth Group, and WellPoint are Motley Fool Inside Value selections. UnitedHealth Group is a Stock Advisor recommendation.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool owns shares of and has written puts on Medtronic and owns shares of UnitedHealth Group. The Fool's disclosure policy likes the peanuts-and-beer version of concessions better.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.18 (-0.69%) $0.60
Aetna Inc. Stock Quote
Aetna Inc.
AET
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.83 (-0.57%) $0.25
UnitedHealth Group Incorporated Stock Quote
UnitedHealth Group Incorporated
UNH
$508.36 (-1.02%) $-5.25
Medtronic plc Stock Quote
Medtronic plc
MDT
$81.33 (-1.61%) $-1.33
Boston Scientific Corporation Stock Quote
Boston Scientific Corporation
BSX
$38.36 (-1.39%) $0.54
Elevance Health Inc. Stock Quote
Elevance Health Inc.
ELV
$448.14 (-1.26%) $-5.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.